Hosted by Anna D. Burke, MD. In this presentation, attendees will learn about current diagnostic algorithms for detection of Alzheimer's disease. We will discuss the role of emerging biomarker assessments and digital cognitive assessments in improving early and accurate diagnosis of Alzheimer's disease.
NOW AVAILABLE!
Read moreAlzheimer's disease (AD) is a neurodegenerative disorder that affects the central nervous system and is characterized by a gradual decline in memory, logical reasoning, and language function (Ballard et al., 2011). The increasing prevalence of AD in the aging population has resulted in this condition becoming recognized as a considerable medical and social challenge for humanity.
August 2023
Read moreγ-Secretase, called “the proteasome of the membrane”, is a membrane-embedded protease complex that cleaves 150+ peptide substrates with central roles in biology and medicine, including amyloid precursor protein and the Notch family of cell-surface receptors. Mutations in γ-secretase and amyloid precursor protein lead to early-onset familial Alzheimer's disease.
March 2024
Read moreAlzheimer's disease (AD) is the most common neurodegenerative disease worldwide which unfortunately has no known effective cure to date. Despite many clinical trials indicating the effectiveness of preclinical treatment, a sensitive tool for screening of AD is yet to be developed.
April 2020
Read moreThe prevalence of Alzheimer's disease and other forms of dementia is increasing along with overall life expectancy, which poses a serious challenge to healthcare systems in general. Non-pharmacological therapies, such as physical activity, have gained popularity due to their potential to improve cognitive and motor function, particularly as the prevalence of dementia is predicted to increase with overall life expectancy.
March 2024
Read moreCaffeine is the most commonly used stimulant drug in the world. Increasing evidence has indicated that caffeine may have a neuroprotective effect in delaying the onset or treatment of several neurodegenerative disorders, especially Alzheimer's disease (AD).
April/June 2023
Read moreAll human beings undergo a lifelong cumulative exposure to potentially preventable adverse factors such as toxins, infections, traumatisms, and cardiovascular risk factors, collectively termed exposome. The interplay between the individual's genetics and exposome is thought to have a large impact in health outcomes such as cancer and cardiovascular disease.
April 2024
Read moreThe aim of this paper is to summarize the latest work on neuroimaging in atypical Alzheimer's disease (AD) patients and to emphasize innovative aspects in the clinic and research. The paper will mostly cover language (logopenic variant of primary progressive aphasia; lvPPA), visual (posterior cortical atrophy; PCA), behavioral (bvAD) and dysexecutive (dAD) variants of AD.
August 2023
Read moreAlzheimer's disease (AD) is a progressive incurable disease affecting an individual's cognitive, behavioral, and physical systems. As individuals become more impaired, assistance is required and care may be provided by spouses, family members, or other close companions who serve as informal caregivers.
September/October 2023
Read more